Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
Why now
Thesis: GLP-1 competition intensifies between Novo and Lilly
Catalyst to watch: Trial data or obesity drug sales figures
Main risk: Novo loses further share to Lilly
Why it matters
Novo's turnaround bet against Lilly's GLP-1 advantages frames a competitive obesity market where share shifts drive revenue outlooks.
Details
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
Sources
- cnbc · 2026-09-25 11:00 UTC